Olaparib

Search with Google Search with Bing

Information
Drug Name
Olaparib
Description
Entry(CIViC)
39
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
prostate cancer MRE11 FRAMESHIFT MUTATION
( ENST00000323929.8 ) MRE11 FRAMESHIFT MUTATION
( ENST00000323929.8 ) 		B Predictive Supports Sensitivity/Response Somatic 2 26510020 Detail
cancer BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION A Predictive Supports Sensitivity/Response Rare Germline 4 19553641 Detail
cancer BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION A Predictive Supports Sensitivity/Response Rare Germline 4 19553641 Detail
ovarian cancer BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Rare Germline 3 25218906 Detail
ovarian cancer BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Rare Germline 3 25218906 Detail
ovarian cancer BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Rare Germline 3 21862407 Detail
ovarian cancer BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Rare Germline 3 21862407 Detail
triple-receptor negative breast cancer BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION B Predictive Supports Resistance Rare Germline 3 21862407 Detail
triple-receptor negative breast cancer BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION B Predictive Does Not Support Sensitivity/Response Rare Germline 3 21862407 Detail
mantle cell lymphoma ATM MUTATION ATM MUTATION D Predictive Supports Sensitivity/Response Somatic 3 20124459 Detail
prostate cancer ATM MUTATION ATM MUTATION C Predictive Supports Sensitivity/Response Rare Germline 3 26510020 Detail
prostate cancer PALB2 BIALLELIC INACTIVATION PALB2 BIALLELIC INACTIVATION C Predictive Supports Sensitivity/Response Somatic 3 26510020 Detail
ovarian cancer BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Rare Germline 4 23346317 Detail
ovarian cancer BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Rare Germline 4 23346317 Detail
brain glioma IDH1 MUTATION IDH1 MUTATION D Predictive Supports Sensitivity/Response Somatic 3 28148839 Detail
lung small cell carcinoma MYC OVEREXPRESSION MYC OVEREXPRESSION D Predictive Supports Sensitivity/Response Somatic 4 28490518 Detail
hematologic cancer ATM MUTATION ATM MUTATION D Predictive Supports Sensitivity/Response Somatic 5 20739657 Detail
ovarian cancer BRCA1 p.Trp1836Ter (p.W1836*)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000713676.1 ) BRCA1 p.Trp1836Ter (p.W1836*)
( ENST00000471181.7, ENST00000591534.5, ENST00000491747.6, ENST00000352993.7, ENST00000357654.9, ENST00000591849.5, ENST00000586385.5, ENST00000493795.5, ENST00000470026.6, ENST00000468300.5, ENST00000461574.2, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000713676.1 ) 		D Predictive Supports Sensitivity/Response Somatic 23415752 Detail
lung small cell carcinoma CHEK1 OVEREXPRESSION CHEK1 OVEREXPRESSION D Predictive Supports Sensitivity/Response N/A 4 28490518 Detail
stomach cancer ATM UNDEREXPRESSION
( ENST00000278616.10 ) ATM UNDEREXPRESSION
( ENST00000278616.10 ) 		B Predictive Supports N/A 1 26282658 Detail
Her2-receptor negative breast cancer BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Rare Germline 5 28578601 Detail
Her2-receptor negative breast cancer BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Rare Germline 3 28578601 Detail
breast cancer BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Rare Germline 4 28792849 Detail
breast cancer BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Rare Germline 4 28792849 Detail
pancreatic cancer BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Rare Germline 4 25366685 Detail
pancreatic cancer BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Rare Germline 4 25366685 Detail
malignant mesothelioma BAP1 ALTERNATIVE TRANSCRIPT (ATI) BAP1 ALTERNATIVE TRANSCRIPT (ATI) D Predictive Supports Sensitivity/Response Somatic 3 28389374 Detail
colorectal cancer BARD1 MUTATION BARD1 MUTATION D Predictive Sensitivity/Response Somatic 3 27197561 Detail
pancreatic cancer BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Rare Germline 3 25366685 Detail
pancreatic cancer BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response 3 25366685 Detail
ovarian serous carcinoma CDK12 LOSS-OF-FUNCTION CDK12 LOSS-OF-FUNCTION D Predictive Supports Sensitivity/Response Somatic 4 24240700 Detail
prostate cancer ATM p.Ser2289Ter (p.S2289*)
( ENST00000278616.10, ENST00000452508.7, ENST00000601453.3, ENST00000675843.1, ENST00000713844.1, ENST00000525729.5 ) ATM p.Ser2289Ter (p.S2289*)
( ENST00000713844.1, ENST00000675843.1, ENST00000452508.7, ENST00000278616.10, ENST00000525729.5, ENST00000601453.3 ) 		C Predictive Supports Sensitivity/Response Somatic 3 26510020 Detail
prostate cancer ATM p.Asn2875His (p.N2875H)
( ENST00000525729.5, ENST00000452508.7, ENST00000278616.10, ENST00000675843.1, ENST00000601453.3, ENST00000615746.4, ENST00000713844.1 ) ATM p.Asn2875His (p.N2875H)
( ENST00000278616.10, ENST00000452508.7, ENST00000601453.3, ENST00000675843.1, ENST00000713844.1, ENST00000525729.5, ENST00000615746.4 ) 		C Predictive Supports Sensitivity/Response Somatic 3 26510020 Detail
prostate cancer BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Somatic 4 26510020 Detail
malignant peripheral nerve sheath tumor PARP1 OVEREXPRESSION PARP1 OVEREXPRESSION D Predictive Supports Sensitivity/Response N/A 3 26650448 Detail
glioblastoma BRCA2 COPY-NEUTRAL LOSS OF HETEROZYGOSITY BRCA2 COPY-NEUTRAL LOSS OF HETEROZYGOSITY C Predictive Supports Sensitivity/Response Unknown 3 31619547 Detail
cancer CBLC EXPRESSION CBLC EXPRESSION D Predictive Supports Resistance N/A 2 25883215 Detail
prostate cancer BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION C Predictive Supports Sensitivity/Response Somatic 2 26510020 Detail
gastric adenocarcinoma ATM UNDEREXPRESSION
( ENST00000278616.10 ) ATM UNDEREXPRESSION
( ENST00000278616.10 ) 		D Predictive Supports Sensitivity/Response N/A 4 24841718 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
One patient in a cohort of 50 patients with metast... MRE11 MRE11 FRAMESHIFT MUTATION
( ENST00000323929.8 ) MRE11 FRAMESHIFT MUTATION
( ENST00000323929.8 ) 		Sensitivity true CIViC Evidence detail
In this phase 1 trial, 60 patients with advanced s... BRCA1 BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
In this phase 1 trial 60 patients with advanced so... BRCA2 BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
46 women with platinum-sensitive, high-grade, BRCA... BRCA1 BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
46 women with platinum-sensitive, high-grade, BRCA... BRCA2 BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
In a study of 63 patients with ovarian cancer, 17 ... BRCA1 BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
In a study of 63 patients with ovarian cancer, 17 ... BRCA2 BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
In a study of 26 patients with breast cancer, 10 p... BRCA1 BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION Resitance or Non-Reponse true CIViC Evidence detail
In a study of 26 patients with breast cancer, 10 p... BRCA2 BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION Sensitivity false CIViC Evidence detail
Two ATM deficient mantle cell lymphoma (MCL) cell ... ATM ATM MUTATION ATM MUTATION Sensitivity true CIViC Evidence detail
Response to olaparib was observed in 4 of 5 with p... ATM ATM MUTATION ATM MUTATION Sensitivity true CIViC Evidence detail
From 14 prostate cancer patients (88%) who had a r... PALB2 PALB2 BIALLELIC INACTIVATION PALB2 BIALLELIC INACTIVATION Sensitivity true CIViC Evidence detail
The combination of PARP inhibition (Olaparib) with... BRCA1 BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
The combination of PARP inhibition (Olaparib) with... BRCA2 BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
Mutations in isocitrate dehydrogenase 1 and 2, whi... IDH1 IDH1 MUTATION IDH1 MUTATION Sensitivity true CIViC Evidence detail
A preclinical study to evaluate the efficacy of ta... MYC MYC OVEREXPRESSION MYC OVEREXPRESSION Sensitivity true CIViC Evidence detail
Olaparib was found to inhibit cancer cell growth i... ATM ATM MUTATION ATM MUTATION Sensitivity true CIViC Evidence detail
In an in vitro study, a SNU-251 cell line expressi... BRCA1 BRCA1 p.Trp1836Ter (p.W1836*)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000713676.1 ) BRCA1 p.Trp1836Ter (p.W1836*)
( ENST00000471181.7, ENST00000591534.5, ENST00000491747.6, ENST00000352993.7, ENST00000357654.9, ENST00000591849.5, ENST00000586385.5, ENST00000493795.5, ENST00000470026.6, ENST00000468300.5, ENST00000461574.2, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000713676.1 ) 		Sensitivity true CIViC Evidence detail
A preclinical study to evaluate the efficacy of ta... CHEK1 CHEK1 OVEREXPRESSION CHEK1 OVEREXPRESSION Sensitivity true CIViC Evidence detail
A randomized phase 2 trial investigating the effic... ATM ATM UNDEREXPRESSION
( ENST00000278616.10 ) ATM UNDEREXPRESSION
( ENST00000278616.10 ) 		N/A true CIViC Evidence detail
302 patients (234 with progression events) with HE... BRCA1 BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
302 patients (234 with progression events) with HE... BRCA2 BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
Randomized, open-label, phase 3 trial in which ola... BRCA1 BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
Randomized, open-label, phase 3 trial in which ola... BRCA2 BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
Twenty-three patients with pancreatic cancer havor... BRCA2 BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
Twenty-three patients with pancreatic cancer havor... BRCA1 BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
Novel alternative splice isoform of BAP1 (BAP1Δ) t... BAP1 BAP1 ALTERNATIVE TRANSCRIPT (ATI) BAP1 ALTERNATIVE TRANSCRIPT (ATI) Sensitivity true CIViC Evidence detail
Loss of BARD1 function through the expression of a... BARD1 BARD1 MUTATION BARD1 MUTATION Sensitivity false CIViC Evidence detail
In multicenter phase II study included individuals... BRCA1 BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
In multicenter phase II study included individuals... BRCA2 BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
In models of high-grade serous ovarian cancer (HGS... CDK12 CDK12 LOSS-OF-FUNCTION CDK12 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
Treatment with the PARP inhibitor olaparib in pati... ATM ATM p.Ser2289Ter (p.S2289*)
( ENST00000278616.10, ENST00000452508.7, ENST00000601453.3, ENST00000675843.1, ENST00000713844.1, ENST00000525729.5 ) ATM p.Ser2289Ter (p.S2289*)
( ENST00000713844.1, ENST00000675843.1, ENST00000452508.7, ENST00000278616.10, ENST00000525729.5, ENST00000601453.3 ) 		Sensitivity true CIViC Evidence detail
Treatment with the PARP inhibitor olaparib in pati... ATM ATM p.Asn2875His (p.N2875H)
( ENST00000525729.5, ENST00000452508.7, ENST00000278616.10, ENST00000675843.1, ENST00000601453.3, ENST00000615746.4, ENST00000713844.1 ) ATM p.Asn2875His (p.N2875H)
( ENST00000278616.10, ENST00000452508.7, ENST00000601453.3, ENST00000675843.1, ENST00000713844.1, ENST00000525729.5, ENST00000615746.4 ) 		Sensitivity true CIViC Evidence detail
In a phase 2 trial of patients with metastatic, ca... BRCA2 BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
The majority of MPNST samples were positive for PA... PARP1 PARP1 OVEREXPRESSION PARP1 OVEREXPRESSION Sensitivity true CIViC Evidence detail
In a case report, a 3‐year‐old girl with glioblast... BRCA2 BRCA2 COPY-NEUTRAL LOSS OF HETEROZYGOSITY BRCA2 COPY-NEUTRAL LOSS OF HETEROZYGOSITY Sensitivity true CIViC Evidence detail
The E3 ubiquitin ligase, CBLC, was identified as a... CBLC CBLC EXPRESSION CBLC EXPRESSION Resitance or Non-Reponse true CIViC Evidence detail
1/1 patients with BRCA1 homozygous deletion had a ... BRCA1 BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
Low ATM protein expression led to sensitivity to P... ATM ATM UNDEREXPRESSION
( ENST00000278616.10 ) ATM UNDEREXPRESSION
( ENST00000278616.10 ) 		Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT03842228 Active, not recruiting Phase 1 Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations November 21, 2019 December 31, 2024
NCT02229656 Active, not recruiting Phase 1 Olaparib and Radiotherapy in Head and Neck Cancer September 24, 2014 January 2024
NCT02893917 Active, not recruiting Phase 2 Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer August 11, 2017 June 7, 2025
NCT03851614 Active, not recruiting Phase 2 Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors April 8, 2019 January 1, 2025
NCT04729387 Active, not recruiting Phase 3 Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected July 2, 2021 January 31, 2026
NCT01081951 Active, not recruiting Phase 2 Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer February 4, 2010 December 31, 2024
NCT02953457 Active, not recruiting Phase 2 Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation June 29, 2017 October 15, 2024
NCT02974621 Active, not recruiting Phase 2 Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma December 7, 2017 July 20, 2024
NCT02299999 Active, not recruiting Phase 2 SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer April 7, 2014 December 2024
NCT02308072 Active, not recruiting Phase 1 Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer September 2015 February 2025
NCT03008278 Active, not recruiting Phase 1/Phase 2 Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery February 6, 2018 June 30, 2024
NCT02032823 Active, not recruiting Phase 3 Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer April 22, 2014 May 28, 2029
NCT03012321 Active, not recruiting Phase 2 Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects January 12, 2017 January 16, 2027
NCT04269200 Active, not recruiting Phase 3 Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer May 5, 2020 March 5, 2025
NCT01116648 Active, not recruiting Phase 1/Phase 2 Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer April 14, 2010 February 13, 2025
NCT03047135 Active, not recruiting Phase 2 Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis March 1, 2017 February 1, 2025
NCT04197713 Active, not recruiting Phase 1 Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study June 30, 2020 September 21, 2024
NCT03737643 Active, not recruiting Phase 3 Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients January 4, 2019 May 25, 2028
NCT02345265 Active, not recruiting Phase 2 Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer May 23, 2016 August 9, 2024
NCT05457257 Active, not recruiting Phase 4 Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations July 29, 2022 September 30, 2025
NCT03880019 Active, not recruiting Phase 2 A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma August 19, 2019 September 21, 2024
NCT02419495 Active, not recruiting Phase 1 Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies June 26, 2015 December 31, 2024
NCT04191135 Active, not recruiting Phase 2 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) December 19, 2019 November 18, 2025
NCT03732820 Active, not recruiting Phase 3 Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer October 31, 2018 April 28, 2026
NCT02446600 Active, not recruiting Phase 3 Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer March 28, 2016 August 9, 2024
NCT03162627 Active, not recruiting Phase 1 Selumetinib and Olaparib in Solid Tumors August 4, 2017 August 30, 2026
NCT04643379 Active, not recruiting Phase 2 Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma August 7, 2021 November 30, 2026
NCT03787680 Active, not recruiting Phase 2 Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial) October 31, 2019 January 2027
NCT03943173 Active, not recruiting Early Phase 1 Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery June 7, 2019 March 22, 2024
NCT03212274 Active, not recruiting Phase 2 Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations January 30, 2019 July 31, 2024
NCT03685331 Active, not recruiting Phase 1 HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer October 15, 2020 April 2024
NCT03233204 Active, not recruiting Phase 2 Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) September 14, 2017 September 22, 2024
NCT04641728 Active, not recruiting Phase 2 Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer January 1, 2021 December 31, 2023
NCT04532645 Active, not recruiting Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK December 11, 2020 December 31, 2024
NCT03259503 Active, not recruiting Phase 1 Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant September 13, 2019 July 31, 2024
NCT03263650 Active, not recruiting Phase 2 Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC October 3, 2017 June 30, 2024
NCT04483544 Active, not recruiting Phase 2 Pembrolizumab and Olaparib in Cervical Cancer Patients December 3, 2020 November 1, 2031
NCT03953898 Active, not recruiting Phase 2 Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation August 4, 2020 December 1, 2024
NCT04123366 Active, not recruiting Phase 2 Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) November 18, 2019 July 24, 2025
NCT05268510 Active, not recruiting Phase 2 Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib as Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma September 15, 2022 March 2027
NCT03660826 Active, not recruiting Phase 2 Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone September 27, 2018 December 31, 2024
NCT03334617 Active, not recruiting Phase 2 Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy December 18, 2017 September 4, 2024
NCT03344965 Active, not recruiting Phase 2 Olaparib In Metastatic Breast Cancer April 1, 2018 December 30, 2024
NCT02489006 Active, not recruiting Phase 2 A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer July 19, 2016 December 31, 2025
NCT02498613 Active, not recruiting Phase 2 A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors August 31, 2016 April 10, 2025
NCT02502266 Active, not recruiting Phase 2/Phase 3 Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer May 3, 2016 June 30, 2024
NCT03976323 Active, not recruiting Phase 3 Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Non-squamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) June 28, 2019 January 13, 2025
NCT03976362 Active, not recruiting Phase 3 A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) June 28, 2019 March 12, 2025
NCT02000622 Active, not recruiting Phase 3 Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. March 27, 2014 December 31, 2024
NCT05171816 Active, not recruiting Phase 3 Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) June 24, 2021 April 28, 2026
NCT03459846 Active, not recruiting Phase 2 A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) March 16, 2018 December 31, 2024
NCT02546661 Active, not recruiting Phase 1 Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer October 3, 2016 June 28, 2024
NCT03498521 Active, not recruiting Phase 2 A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site July 10, 2018 June 9, 2024
NCT05156268 Active, not recruiting Phase 2 A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma January 27, 2022 January 2025
NCT02571725 Active, not recruiting Phase 1/Phase 2 PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer February 23, 2016 July 15, 2027
NCT04306367 Active, not recruiting Phase 2 Study of Pembrolizumab and Olaparib in Bile Duct Cancer April 1, 2020 December 1, 2023
NCT04034927 Active, not recruiting Phase 2 Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer December 4, 2019 September 21, 2024
NCT03641755 Active, not recruiting Phase 1 Olaparib + Sapacitabine in BRCA Mutant Breast Cancer October 1, 2018 June 22, 2025
NCT04380636 Active, not recruiting Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) July 6, 2020 February 15, 2027
NCT04336943 Active, not recruiting Phase 2 Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load April 13, 2021 June 6, 2025
NCT03579784 Active, not recruiting Phase 2 Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer November 26, 2018 December 31, 2024
NCT01858168 Active, not recruiting Phase 1 Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma July 2013 December 2024
NCT04298021 Active, not recruiting Phase 2 DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer June 25, 2020 December 31, 2024
NCT03740165 Active, not recruiting Phase 3 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) December 18, 2018 May 29, 2026
NCT04931342 Active, not recruiting Phase 2 A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors October 7, 2021 December 31, 2028
NCT03775486 Active, not recruiting Phase 2 Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) December 21, 2018 September 27, 2024
NCT02734004 Active, not recruiting Phase 1/Phase 2 A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. March 17, 2016 September 17, 2025
NCT04053322 Active, not recruiting Phase 2 Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. August 26, 2019 August 2027
NCT04076579 Active, not recruiting Phase 2 Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma March 17, 2020 January 2025
NCT02208375 Active, not recruiting Phase 1/Phase 2 mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian November 11, 2014 December 30, 2025
NCT01078662 Active, not recruiting Phase 2 Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats February 21, 2010 December 31, 2024
NCT04739800 Active, not recruiting Phase 2 Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents June 10, 2021 January 8, 2025
NCT02849496 Active, not recruiting Phase 2 Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer March 30, 2017 August 31, 2024
NCT01851265 Completed Phase 1 D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours July 4, 2013 June 6, 2017
NCT01924533 Completed Phase 3 Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. September 3, 2013 March 27, 2023
NCT01972217 Completed Phase 2 Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer. April 1, 2014 August 24, 2023
NCT03834519 Completed Phase 3 Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) May 2, 2019 January 27, 2024
NCT04152941 Completed Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients October 11, 2018 February 11, 2020
NCT02093351 Completed Phase 1 To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer September 1, 2014 April 29, 2019
NCT02117167 Completed Phase 2 SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients April 23, 2014 December 2023
NCT02121990 Completed Phase 1 Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer April 21, 2014 August 19, 2020
NCT02184195 Completed Phase 3 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy December 16, 2014 January 27, 2023
NCT02227082 Completed Phase 1 Olaparib and Radiotherapy in Inoperable Breast Cancer October 21, 2013 August 2020
NCT02282020 Completed Phase 3 Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments February 6, 2015 July 19, 2022
NCT02324998 Completed Phase 1 Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy December 2016 May 2019
NCT02338622 Completed Phase 1 Trial of Olaparib in Combination With AZD5363 (ComPAKT) March 31, 2014 March 21, 2017
NCT02340611 Completed Phase 2 A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib June 2015 June 2018
NCT02398058 Completed Phase 1 Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS) July 20, 2014 December 1, 2019
NCT02430311 Completed Phase 1 The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. June 10, 2015 April 28, 2017
NCT00494234 Completed Phase 2 Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer June 15, 2007 December 21, 2022
NCT02476968 Completed Phase 4 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer September 28, 2015 December 17, 2021
NCT02477644 Completed Phase 3 Platine, Avastin and OLAparib in 1st Line May 6, 2015 March 22, 2022
NCT00535353 Completed Phase 1 AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer January 2, 2008 February 13, 2015
NCT02506816 Completed Preoperative Olaparib Endometrial Carcinoma Study (POLEN) February 2016 March 2019
NCT02511223 Completed Phase 2 Efficacy and Safety of PARPi to Treat Pancreatic Cancer July 2016 April 18, 2021
NCT02511795 Completed Phase 1 AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors August 6, 2015 October 16, 2019
NCT02588105 Completed Phase 1 Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer November 10, 2015 July 26, 2022
NCT02677038 Completed Phase 2 Olaparib in Treating Patients With Stage IV Pancreatic Cancer November 11, 2016 July 18, 2022
NCT02681237 Completed N/A A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer April 29, 2016 March 25, 2022
NCT00912743 Completed Phase 2 Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status May 2009 March 2012
NCT02755844 Completed Phase 1/Phase 2 Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients September 23, 2016 June 2020
NCT01063517 Completed Phase 2 Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients February 2, 2010 June 29, 2023
NCT02787642 Completed Phase 1 A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma January 2016 May 2022
NCT02855697 Completed Early Phase 1 Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer May 26, 2017 December 31, 2021
NCT02882308 Completed Phase 2 Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck. October 20, 2016 January 10, 2020
NCT02898207 Completed Phase 1 Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer May 19, 2017 January 14, 2022
NCT02983799 Completed Phase 2 Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status December 22, 2016 December 3, 2020
NCT02987543 Completed Phase 3 Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) February 6, 2017 February 15, 2023
NCT03009682 Completed Phase 2 Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations August 2016 January 2021
NCT03022409 Completed Phase 1 A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC). September 18, 2017 January 20, 2021
NCT03057145 Completed Phase 1 Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors March 10, 2017 June 9, 2021
NCT01237067 Completed Phase 1 Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers February 7, 2011 December 12, 2019
NCT03109080 Completed Phase 1 Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) July 24, 2017 November 29, 2021
NCT03117933 Completed Phase 2 Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer March 9, 2017 December 31, 2023
NCT03127215 Completed Phase 2 Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors October 25, 2018 December 19, 2023
NCT01390571 Completed Phase 1 Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma July 2011 June 20, 2017
NCT03161132 Completed Phase 2 Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin December 13, 2017 December 31, 2022
NCT03205176 Completed Phase 1 AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas June 30, 2017 April 8, 2021
NCT03205761 Completed Phase 2 Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer October 23, 2017 December 15, 2022
NCT03286842 Completed Phase 3 To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients. January 17, 2018 October 8, 2021
NCT01562210 Completed Phase 1 Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC April 2012 March 13, 2020
NCT04456699 Completed Phase 3 Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) August 19, 2020 November 6, 2023
NCT04417192 Completed Phase 2 Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer December 1, 2020 June 30, 2023
NCT01583543 Completed Phase 2 Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma May 2012 November 2014
NCT03378297 Completed Early Phase 1 IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC May 4, 2018 January 5, 2023
NCT03402841 Completed Phase 3 Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients January 30, 2018 March 10, 2022
NCT03428607 Completed Phase 2 Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] October 17, 2018 January 15, 2021
NCT03434158 Completed Phase 2 Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) February 6, 2018 May 12, 2022
NCT03448718 Completed Phase 2 Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations April 17, 2018 October 15, 2021
NCT03470805 Completed Phase 2 Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma June 21, 2018 July 27, 2022
NCT03516812 Completed Phase 2 Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer August 29, 2018 April 12, 2024
NCT03531840 Completed Phase 2 Olaparib in People With Malignant Mesothelioma July 11, 2018 October 21, 2020
NCT03534492 Completed Phase 2 Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB) November 16, 2018 March 16, 2020
NCT03544125 Completed Phase 1 Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer May 3, 2018 November 18, 2020
NCT04330040 Completed Phase 4 Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer May 30, 2020 September 30, 2022
NCT01758731 Completed Phase 1 Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History October 22, 2012 October 31, 2018
NCT01813474 Completed Phase 1 Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies March 25, 2013 August 31, 2016
NCT04421963 Enrolling by invitation Phase 3 Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib August 4, 2020 December 10, 2024
NCT03063710 No longer available Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan
NCT06419179 Not yet recruiting Phase 2 Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) September 2024 December 2026
NCT06441747 Not yet recruiting Phase 2 Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) August 2024 August 2028
NCT05093231 Not yet recruiting Phase 2 Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer June 17, 2024 May 4, 2026
NCT05900895 Not yet recruiting Phase 1 Estradiol Plus Olaparib for Breast Cancer (PHOEBE) May 2024 December 2028
NCT05522491 Not yet recruiting Phase 2 Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer September 1, 2022 September 1, 2024
NCT05949424 Not yet recruiting Phase 4 OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults May 2024 March 2025
NCT05536128 Not yet recruiting Phase 2 Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor December 31, 2022 December 31, 2025
NCT05128734 Not yet recruiting Phase 2 Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) July 1, 2024 July 1, 2028
NCT05411094 Recruiting Phase 1 Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer May 22, 2023 March 31, 2025
NCT02484404 Recruiting Phase 1/Phase 2 Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... June 29, 2015 December 30, 2025
NCT02693535 Recruiting Phase 2 TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer March 14, 2016 December 31, 2025
NCT02769962 Recruiting Phase 1/Phase 2 Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer May 9, 2016 December 31, 2027
NCT02813135 Recruiting Phase 1/Phase 2 European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors August 3, 2016 August 2027
NCT02925234 Recruiting Phase 2 The Drug Rediscovery Protocol (DRUP Trial) August 2016 December 2027
NCT03025035 Recruiting Phase 2 Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer September 10, 2017 August 8, 2026
NCT03085147 Recruiting Phase 1/Phase 2 A Dye for the Detection of Cancer of the Tongue and Mouth March 15, 2017 July 2026
NCT03150576 Recruiting Phase 2/Phase 3 Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer May 2016 June 2034
NCT03155620 Recruiting Phase 2 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) July 31, 2017 September 30, 2027
NCT03212742 Recruiting Phase 1/Phase 2 Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients September 4, 2017 March 4, 2025
NCT03297606 Recruiting Phase 2 Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) March 23, 2018 January 31, 2027
NCT03375307 Recruiting Phase 2 Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes November 3, 2020 August 21, 2024
NCT03568656 Recruiting Phase 1/Phase 2 Study to Evaluate CCS1477 in Advanced Tumours July 23, 2018 March 2024
NCT03579316 Recruiting Phase 2 Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer December 7, 2018 December 30, 2024
NCT03598257 Recruiting Phase 2 Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer January 18, 2019 June 1, 2027
NCT03682289 Recruiting Phase 2 Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors January 17, 2019 July 31, 2025
NCT03740893 Recruiting Phase 2 PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer October 15, 2019 December 2025
NCT03741426 Recruiting Phase 2 WIRE - Novel Treatments in Renal Cell Cancer July 27, 2020 November 30, 2025
NCT03742245 Recruiting Phase 1 Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer June 11, 2019 March 1, 2026
NCT03742895 Recruiting Phase 2 Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) December 12, 2018 June 30, 2026
NCT03782818 Recruiting Phase 1/Phase 2 Olaparib for PAH: a Multicenter Clinical Trial November 20, 2019 March 2024
NCT03786796 Recruiting Phase 2 Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations June 3, 2019 March 2026
NCT03801369 Recruiting Phase 2 Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer December 12, 2018 December 31, 2027
NCT03874884 Recruiting Phase 1 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer July 9, 2019 June 2026
NCT03991832 Recruiting Phase 2 Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors December 31, 2019 March 31, 2025
NCT04005690 Recruiting Early Phase 1 Targeted Pathway Inhibition in Patients With Pancreatic Cancer August 1, 2019 February 1, 2028
NCT04038502 Recruiting Phase 2 Carboplatin or Olaparib for BRcA Deficient Prostate Cancer October 1, 2019 August 29, 2025
NCT04042831 Recruiting Phase 2 Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations June 24, 2020 March 30, 2025
NCT04633239 Recruiting Phase 1 Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer July 2, 2021 December 1, 2024
NCT04633902 Recruiting Phase 2 Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation March 3, 2021 December 31, 2024
NCT04644289 Recruiting Phase 2 WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC May 5, 2022 June 2028
NCT04666740 Recruiting Phase 2 A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy December 18, 2020 January 2025
NCT04683679 Recruiting Phase 2 A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer April 21, 2021 January 2025
NCT04711824 Recruiting Phase 1/Phase 2 Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases March 9, 2022 September 2026
NCT04728230 Recruiting Phase 1/Phase 2 Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial January 5, 2021 December 31, 2025
NCT04748042 Recruiting Phase 2 Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) May 28, 2021 May 2025
NCT04753879 Recruiting Phase 2 Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. September 29, 2021 December 1, 2029
NCT04826198 Recruiting Phase 1/Phase 2 Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months October 5, 2020 October 2023
NCT04858334 Recruiting Phase 2 APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation June 22, 2021 October 31, 2027
NCT04884360 Recruiting Phase 3 D9319C00001- 1L OC Mono Global RCT May 31, 2021 July 2, 2025
NCT05078671 Recruiting Phase 4 Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness December 15, 2021 December 31, 2025
NCT05158062 Recruiting Phase 2 Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer April 20, 2022 November 30, 2024
NCT05174832 Recruiting Phase 2 Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients September 7, 2022 March 1, 2025
NCT05201612 Recruiting Phase 2 Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC). July 7, 2022 March 2025
NCT05203445 Recruiting Phase 2 A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer January 31, 2022 January 2026
NCT05222971 Recruiting Phase 2 Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy April 1, 2022 December 30, 2025
NCT05240898 Recruiting Phase 1 A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors August 16, 2021 June 30, 2027
NCT05252390 Recruiting Phase 1/Phase 2 NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors March 29, 2022 November 2026
NCT05255471 Recruiting Phase 3 MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. January 21, 2022 January 21, 2028
NCT05255653 Recruiting Phase 2/Phase 3 Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features November 11, 2021 January 1, 2031
NCT05286827 Recruiting Phase 2 Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma December 14, 2023 June 1, 2025
NCT05320757 Recruiting Early Phase 1 Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients April 1, 2022 March 31, 2025
NCT05332561 Recruiting Phase 2 Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) June 29, 2023 December 2030
NCT05340413 Recruiting Phase 2 Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. March 25, 2022 June 2024
NCT05366166 Recruiting Phase 2 Pembrolizumab Plus Olaparib in LA-HNSCC September 2, 2022 October 31, 2026
NCT05379972 Recruiting Phase 2 Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers January 12, 2023 December 2028
NCT05432518 Recruiting Early Phase 1 Pilot Trial for Treatment of Recurrent Glioblastoma June 27, 2023 December 1, 2027
NCT05463848 Recruiting Phase 2 Surgical Pembro +/- Olaparib w TMZ for rGBM October 21, 2022 December 1, 2025
NCT05485766 Recruiting Phase 2 Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer February 29, 2024 September 30, 2027
NCT05498272 Recruiting Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations February 1, 2023 December 2026
NCT05501548 Recruiting Phase 2 Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer June 30, 2023 March 2028
NCT05524935 Recruiting Phase 2 Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma October 11, 2022 December 2025
NCT05554328 Recruiting Phase 2 Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial April 25, 2023 October 1, 2028
NCT05564377 Recruiting Phase 2 Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial April 7, 2023 July 1, 2030
NCT05568550 Recruiting Phase 2 Pembro With Radiation With or Without Olaparib July 27, 2023 July 2, 2029
NCT05629429 Recruiting Phase 2 Olaparib Maintenance Therapy in Metastatic Breast Cancer February 7, 2023 December 31, 2025
NCT05700669 Recruiting Phase 1/Phase 2 Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors February 20, 2023 April 2027
NCT05870423 Recruiting Phase 1 Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors June 1, 2022 January 1, 2025
NCT05887609 Recruiting Phase 2 An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib October 3, 2023 December 2027
NCT05898399 Recruiting Phase 1/Phase 2 Study of ART6043 in Advanced/Metastatic Solid Tumors Patients June 30, 2023 December 14, 2026
NCT05932862 Recruiting Phase 1 A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors August 17, 2023 August 3, 2029
NCT06112379 Recruiting Phase 3 A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer November 14, 2023 August 28, 2030
NCT06121401 Recruiting Phase 4 First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients September 15, 2023 September 15, 2027
NCT06130254 Recruiting Phase 1 Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers January 30, 2024 August 25, 2030
NCT06177171 Recruiting Phase 1 Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors February 7, 2024 November 1, 2026
NCT06217757 Recruiting Phase 1/Phase 2 Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC April 18, 2024 March 20, 2027
NCT06245889 Recruiting Phase 2 PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC May 1, 2024 June 2030
NCT06298084 Recruiting Phase 1/Phase 2 Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd March 21, 2024 June 2029
NCT06353386 Recruiting Phase 1/Phase 2 Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) May 20, 2024 March 31, 2028
NCT06377267 Recruiting Phase 2 Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) February 6, 2024 September 2025
NCT04086485 Recruiting Phase 1/Phase 2 Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) October 3, 2022 January 1, 2026
NCT04090567 Recruiting Phase 2 Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer July 28, 2020 March 31, 2025
NCT04209686 Recruiting Phase 2 Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma July 31, 2020 April 2028
NCT04236414 Recruiting Phase 1 Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours January 14, 2020 December 30, 2025
NCT04394858 Recruiting Phase 2 Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer March 17, 2021 February 28, 2025
NCT04417062 Recruiting Phase 2 Olaparib With Ceralasertib in Recurrent Osteosarcoma November 24, 2020 June 1, 2025
NCT04515836 Recruiting Phase 2 Olaparib in Patients With HRD Malignant Mesothelioma February 19, 2021 October 15, 2025
NCT04538378 Recruiting Phase 2 Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors July 7, 2021 December 31, 2026
NCT04548752 Recruiting Phase 2 Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations February 22, 2021 March 31, 2025
NCT04614909 Recruiting Early Phase 1 Study of Pamiparib in Newly Diagnosed and rGBM January 11, 2021 December 2024
NCT03878095 Suspended Phase 2 Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors January 30, 2020 March 1, 2025
NCT04585958 Suspended Phase 1 Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer May 21, 2021 June 30, 2024
NCT03317392 Suspended Phase 1/Phase 2 Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis February 4, 2019 November 30, 2024
NCT05432791 Suspended Phase 2/Phase 3 Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working March 30, 2023 March 9, 2030
NCT03251872 Terminated Early Phase 1 Olaparib for PAH: a Pilot Study October 25, 2018 December 1, 2019
NCT03810105 Terminated Phase 2 A Study of Olaparib and Durvalumab in Prostate Cancer March 7, 2019 July 6, 2023
NCT04951492 Terminated Phase 2 Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma November 9, 2022 October 15, 2023
NCT04556617 Terminated Phase 1/Phase 2 PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) September 21, 2020 May 24, 2022
NCT03570476 Terminated Phase 2 Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer September 11, 2018 July 3, 2019
NCT04579133 Terminated Phase 2 Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy March 1, 2021 March 1, 2021
NCT02485990 Terminated Phase 1 Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) January 8, 2016 March 5, 2020
NCT02899728 Terminated Phase 2 Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer March 30, 2018 March 17, 2020
NCT04377087 Terminated Phase 2 Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer June 29, 2020 May 31, 2023
NCT02561832 Terminated Phase 1 A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer November 6, 2015 February 1, 2017
NCT03924245 Terminated Phase 1 Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers October 1, 2020 February 4, 2022
NCT04801966 Terminated N/A Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study September 23, 2021 December 30, 2022
NCT03367689 Terminated Phase 2 A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent April 17, 2018 December 31, 2021
NCT03878524 Terminated Phase 1 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial April 1, 2020 December 10, 2020
NCT06065059 Terminated Phase 1/Phase 2 Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors December 8, 2023 May 22, 2024
NCT01650376 Unknown status Phase 1/Phase 2 Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer August 2012 December 2019
NCT02681562 Unknown status Phase 2 Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients January 2016
NCT03955640 Unknown status Phase 1 Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences May 20, 2019 October 2023
NCT03925233 Unknown status Breast Cancer Treatment Based on Organ-like Culture January 2, 2019 December 15, 2021
NCT02679963 Unknown status Phase 2 Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer January 2016 January 2021
NCT04261465 Unknown status Phase 2 NUVOLA TRIAL Open-label Multicentre Study December 1, 2019 December 1, 2022
NCT03829345 Unknown status Phase 2 A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer July 2, 2019 February 14, 2022
NCT03594396 Unknown status Phase 1/Phase 2 Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer June 29, 2018 December 30, 2022
NCT03570437 Unknown status Phase 2 Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? May 17, 2018 June 30, 2023
NCT01682772 Unknown status Phase 2 TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer July 2012 February 2020
NCT02533765 Unknown status Phase 2 Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor September 11, 2015 June 2021
NCT03314740 Unknown status Phase 2 Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib June 1, 2017 November 30, 2019
NCT03278717 Unknown status Phase 3 Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients June 15, 2018 December 2023
NCT02446704 Unknown status Phase 1/Phase 2 Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy October 13, 2015 December 2023
NCT01460888 Unknown status Phase 1 Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus July 2013 August 2018
NCT04566952 Unknown status Phase 2 Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer October 28, 2020 October 1, 2023
NCT03239015 Unknown status Phase 2 Efficacy and Safety of Precision Therapy in Refractory Tumor January 1, 2017 December 31, 2023
NCT03182634 Unknown status Phase 2 The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial December 15, 2016 November 2023
NCT05262608 Unknown status Phase 2 The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation December 7, 2021 April 26, 2024
NCT02822157 Unknown status Phase 2 Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer August 2016 July 2023
NCT04065269 Unknown status Phase 2 ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss November 27, 2019 March 2023
NCT01788332 Unknown status Phase 2 Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN) January 2014 December 2018
NCT05807126 Withdrawn Phase 1 Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations March 5, 2024 December 6, 2026
NCT05238831 Withdrawn Early Phase 1 SMMART Adaptive Clinical Treatment (ACT) Trial January 30, 2023 May 31, 2026
NCT05967286 Withdrawn Phase 2 Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial October 23, 2023 April 30, 2025
NCT05209529 Withdrawn Phase 2 Chemo-free BRCA-targeted Neoadjuvant Strategy February 1, 2024 July 18, 2030
NCT02686008 Withdrawn Phase 1 Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC January 2018 July 2019
NCT04239014 Withdrawn Phase 2 A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. August 7, 2020 January 25, 2021
NCT05295589 Withdrawn Phase 2 Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy June 30, 2022 March 17, 2023
NCT02392676 Withdrawn Phase 3 Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations July 2016 June 2019
NCT01661868 Withdrawn Phase 2 Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer August 2012 August 2012
NCT05482074 Withdrawn Phase 2 Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 October 4, 2022 May 1, 2027
NCT01491139 Withdrawn Phase 1 Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck